Advaxis (ADXS) Granted U.S. Patent Relating to Axalimogene Filolisbac

March 25, 2019 8:04 AM UTC Send to a Friend
Advaxis, Inc. (NASDAQ: ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login